Aratana Therapeutics Inc (PETX) Expected to Post Quarterly Sales of $5.70 Million

Wall Street analysts forecast that Aratana Therapeutics Inc (NASDAQ:PETX) will post sales of $5.70 million for the current quarter, Zacks reports. Three analysts have made estimates for Aratana Therapeutics’ earnings, with the lowest sales estimate coming in at $5.20 million and the highest estimate coming in at $6.20 million. Aratana Therapeutics reported sales of $6.16 million in the same quarter last year, which would suggest a negative year over year growth rate of 7.5%. The firm is expected to issue its next earnings report on Thursday, November 1st.

On average, analysts expect that Aratana Therapeutics will report full-year sales of $26.80 million for the current year, with estimates ranging from $20.50 million to $38.10 million. For the next financial year, analysts forecast that the firm will report sales of $47.57 million per share, with estimates ranging from $40.10 million to $52.60 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that follow Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. Aratana Therapeutics had a negative return on equity of 35.25% and a negative net margin of 154.23%. The business had revenue of $4.91 million during the quarter, compared to the consensus estimate of $4.72 million.

A number of research analysts have recently commented on the stock. Stifel Nicolaus dropped their price objective on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, August 6th. BidaskClub raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 10th. HC Wainwright set a $10.00 price objective on shares of Aratana Therapeutics and gave the company a “buy” rating in a research note on Monday, May 7th. ValuEngine raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 15th. Finally, Zacks Investment Research raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating and set a $5.50 price objective for the company in a research note on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $8.21.

Aratana Therapeutics traded up $0.06, hitting $5.14, during trading on Friday, Marketbeat.com reports. The stock had a trading volume of 211,201 shares, compared to its average volume of 250,932. Aratana Therapeutics has a 1-year low of $3.67 and a 1-year high of $7.28. The company has a market capitalization of $241.69 million, a price-to-earnings ratio of -5.29 and a beta of 2.78. The company has a current ratio of 3.02, a quick ratio of 2.82 and a debt-to-equity ratio of 0.09.

In other news, COO Brent Standridge sold 10,000 shares of the company’s stock in a transaction dated Monday, June 25th. The shares were sold at an average price of $4.56, for a total transaction of $45,600.00. Following the completion of the transaction, the chief operating officer now owns 99,967 shares of the company’s stock, valued at approximately $455,849.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Peter Steven St sold 11,513 shares of the company’s stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $4.33, for a total transaction of $49,851.29. Following the transaction, the insider now directly owns 649,233 shares of the company’s stock, valued at approximately $2,811,178.89. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,815 shares of company stock valued at $133,057. Corporate insiders own 5.30% of the company’s stock.

Several large investors have recently modified their holdings of the company. Franklin Resources Inc. grew its holdings in shares of Aratana Therapeutics by 0.5% during the 1st quarter. Franklin Resources Inc. now owns 5,969,371 shares of the biopharmaceutical company’s stock worth $26,325,000 after purchasing an additional 28,969 shares during the period. BlackRock Inc. grew its holdings in shares of Aratana Therapeutics by 11.5% during the 2nd quarter. BlackRock Inc. now owns 3,348,240 shares of the biopharmaceutical company’s stock worth $14,231,000 after purchasing an additional 345,204 shares during the period. General American Investors Co. Inc. grew its holdings in shares of Aratana Therapeutics by 44.7% during the 1st quarter. General American Investors Co. Inc. now owns 1,617,923 shares of the biopharmaceutical company’s stock worth $7,135,000 after purchasing an additional 500,000 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Aratana Therapeutics by 36.2% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,376,198 shares of the biopharmaceutical company’s stock worth $5,849,000 after purchasing an additional 365,750 shares during the period. Finally, Millennium Management LLC boosted its holdings in Aratana Therapeutics by 117.0% in the 1st quarter. Millennium Management LLC now owns 1,347,975 shares of the biopharmaceutical company’s stock worth $5,945,000 after acquiring an additional 726,903 shares during the period. Institutional investors and hedge funds own 67.82% of the company’s stock.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Recommended Story: Market Capitalization and Individual Investors

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply